Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23 ...

Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, ...

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of ...

Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Zydus Lifesciences has received a significant approval from the US FDA for Enzalutamide capsules, which are used in treatment ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Zydus Lifesciences share price trading maginally lower in the opening trade on October 3 despite the company received ...

BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and ...